This week’s Innovation Partners BioBlog provides a recap of key company news from the JPM Health Conference. GSK is changing direction and adding to its cancer drug pipeline, while Eli Lilly and Co has indicated it will not, for the time being, pursue CAR-T and gene therapy. Hospitals began complying with the ruling to post ...

This week, the Innovation Partners BioBlog focuses on oncology research and drugs. Eli Lilly purchased Loxo Oncology this week while Sanofi and Regeneron extended and restructure their immune-oncology agreement. Takeda struck three new deals which will help their oncology R & D efforts, and Ribon raised millions to fund clinical trials. This and more in ...

We hope everyone had a wonderful holiday filled with friends, family, and fun! We return now to the world of healthcare innovation where new developments are occurring throughout the industry. In this week’s Innovation Partners BioBlog, we look at the continuing saga of HHS cutting 340B payments and shifts in ObamaCare. Enrollment in ObamaCare continues ...

In this week’s Innovation Partners BioBlog, we share highlights from the world of healthcare. In Texas, a judge deemed the ACA unconstitutional since the individual mandate has dropped to $0. The Cigna/ExpressScripts merger clears another hurdle, and Democrats seek to push forward a bill to block drug price increases it deems “unjustified.” These and more ...

An interesting article in the New York Times invited experts to weigh in on how to cut drug prices without compromising innovation. It’s worth a read and brings up many of the challenges facing the industry. Competition among retail pharmacies finds Walgreens partnering with FedEx to offer same-day delivery service and compete with both Amazon ...

This week’s Innovation Partners BioBlog focuses on the business of healthcare. The CVS-Aetna merger is complete, and experts are watching eagerly to see how the company uses the CVS chain for its planned community-based healthcare initiatives. The FDA has approved a new biosimilar, Rituxan, and Tocagen and NRG Oncology plan to collaborate on a Phase ...

In this week’s Innovation Partners BioBlog, we feature updates on many important stories from the world of healthcare. The FDA is reviewing their 40-year old fast-track process with the goal of updating it to improve medical device safety review procedures. Small, independent hospitals have found a new way to remain solvent without merging with large ...

What lowers costs without compromising the quality of care or value? That's the theme of this week's Innovation Partners BioBlog. We look at the acquisition of Athenahealth and the shift to Virence's value-based care solutions, how value-based care has lowered the costs of Medicare and the impact of generic drugs. These top stories and more ...

In this week's Innovation Partners BioBlog, we share the news that Medicaid won expansion in three states; Montana was the holdout among the four states allowing voters to choose expansion. CMS modified its proposed code changes in responses to an outcry from physicians groups concerned that the code changes would unfairly penalize those treating complex ...

This week, attention focuses on several aspects of Medicare. CMS will delay modifications to E/M codes until 2021 thanks in large part to push back from doctors. Site-neutral payments are in the news related to Medicare along with Medicare Part B. In other news, CVS plans some testing of new programs to address chronic health ...